BAFF-R CART
PreclinicalCell therapy
BAFF-R CART is one of 53 small molecule programs targeting Chronic Inflammatory Demyelinating Polyradiculoneuropathy. It is currently in Preclinical.
2
Indications
1
Total Trials
1
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
131 competitors in Safety and Efficacy
#DrugCompanyPhaseTrials
1Avastin
RochePhase 3
Actemra
RochePhase 3
Humira
RRanbaxy Laboratories Limited
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Empaveli
Apellis PharmaceuticalsPhase 3
Gemzar
Johnson & JohnsonPhase 2
Fludara
SanofiPhase 2
CAB LA
GSKPhase 3
Yervoy
Bristol-Myers SquibbPhase 2
B/F/TAF
GileadPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BAFF-R CART. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details